BOSTON, May 5, 2026
Sensei Biotherapeutics, Inc. has announced the first patient dosing in its Phase 1b/2 clinical trial of PIKTOR, an investigational all-oral, multi-node inhibitor targeting the PI3K/AKT/mTOR signaling pathway in patients with HR+/HER2- advanced breast cancer. This milestone marks a critical step in advancing next-generation oncology therapeutics, particularly for patients with limited treatment options due to resistance to standard therapies.
Multi-Node Targeting Strategy to Overcome Resistance
The Phase 1b/2 trial, known as Study FTH-PIK-101, is a multi-center, dose-escalation study designed to evaluate the safety and efficacy of PIKTOR in combination with fulvestrant and other anticancer therapies. Unlike traditional targeted therapies that inhibit a single node of the PI3K pathway, PIKTOR uniquely combines serabelisib (PI3K-alpha inhibitor) and sapanisertib (dual mTORC1/2 inhibitor) to block multiple signaling pathways simultaneously.
This multi-node inhibition approach is designed to prevent tumor cells from bypassing treatment by activating alternative growth pathways, a common mechanism of resistance in cancer therapy. Approximately 50% of HR+/HER2- breast cancer cases involve alterations in the PI3K/AKT/mTOR pathway, making it a critical target for innovative therapeutic strategies.
Clinical Evidence Supports Promising Therapeutic Potential
Advertisement
Previous clinical studies have demonstrated encouraging results for PIKTOR. In a completed Phase 1b investigator-initiated trial, patients with advanced cancers who had exhausted multiple lines of therapy showed a 47% overall response rate, with 71% response in patients harboring PI3K pathway mutations. Notably, several patients achieved complete responses, highlighting the potential of this combination therapy in heavily pretreated populations.
The current trial expands this research into HR+/HER2- advanced breast cancer, a patient population with significant unmet medical needs. The study is designed to include patients regardless of mutational status, enabling broader evaluation of PIKTOR’s clinical applicability across diverse tumor profiles. Additionally, the trial builds on earlier evidence supporting the efficacy of sapanisertib combined with endocrine therapies, further strengthening the rationale for this multi-targeted approach.
Advancing Oncology Innovation and Clinical Development
The initiation of this trial follows Sensei Biotherapeutics’ acquisition of Faeth Therapeutics in early 2026, which positioned PIKTOR as the company’s lead oncology program. As a clinical-stage biotechnology company, Sensei is focused on developing therapies that address key oncogenic pathways through combination and multi-node inhibition strategies.
This clinical milestone reflects broader trends in oncology research, where combination therapies and pathway-based targeting are increasingly being explored to overcome resistance and improve patient outcomes. By advancing PIKTOR through early-phase clinical development, Sensei aims to contribute to the evolution of precision oncology, where treatments are tailored based on tumor biology and signaling mechanisms.
The ongoing development of PIKTOR also includes additional clinical programs, such as a Phase 2 study in advanced endometrial cancer, further demonstrating its potential across multiple tumor types. This reinforces the role of multi-pathway inhibition as a promising strategy in modern cancer therapeutics.
Implications for Clinical Research and Oncology Therapeutics
The dosing of the first patient in this Phase 1b/2 trial represents an important step in translating preclinical and early clinical findings into broader clinical validation. Early-phase trials such as this are essential for establishing dose optimization, safety profiles, and preliminary efficacy signals, which will inform subsequent late-stage development and regulatory strategies.
As oncology research continues to evolve, therapies like PIKTOR highlight the importance of targeting complex signaling networks rather than single molecular pathways, potentially offering improved outcomes for patients with treatment-resistant cancers. The trial also underscores the role of innovative clinical trial designs in accelerating the development of next-generation cancer therapies.
Source: Sensei Biotherapeutics press release
